Literature DB >> 32653048

Lichenoid Skin Nodules as Presenting Feature of Necrotic Erythema Nodosum Leprosum in Leprosy.

Akanksha Kaushik, Sunil Dogra, Tarun Narang.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32653048      PMCID: PMC7356426          DOI: 10.4269/ajtmh.20-0177

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


× No keyword cloud information.
An 18-year-old male presented with painful papulo-nodular lesions on the upper limbs and back along with high-grade fever since 1 week. Most lesions had a lichenoid center with surrounding blisters (Figure 1A). There was associated tenderness and thickening of bilateral ulnar nerves. Slit skin smear was positive for Mycobacterium leprae (with a bacteriological index of 6+ and a morphological index of 0%) (Figure 1B). Skin biopsy revealed features of lepromatous leprosy (LL) with erythema nodosum leprosum (ENL) including granulomas, nerve destruction, vasculitis, and panniculitis, and lepra stain was positive (Figure 1C). Over the next 2 weeks, most lesions developed ulceration, suggesting necrotic ENL (Figure 1D). The patient is currently receiving WHO-recommended multidrug therapy (MDT) with oral corticosteroids.
Figure 1.

(A) Patient with multiple papulo-nodules, having a lichenoid center with surrounding blisters, on upper limb and back. (B) Slit skin smear of the same patient showing acid fast bacilli. (C) Histopathological examination of skin biopsy showing granulomatous inflammation and vasculitis. (D) Same patient with ulcerative changes in lesions within 2 weeks, suggesting necrotic ENL. This figure appears in color at

(A) Patient with multiple papulo-nodules, having a lichenoid center with surrounding blisters, on upper limb and back. (B) Slit skin smear of the same patient showing acid fast bacilli. (C) Histopathological examination of skin biopsy showing granulomatous inflammation and vasculitis. (D) Same patient with ulcerative changes in lesions within 2 weeks, suggesting necrotic ENL. This figure appears in color at Erythema nodosum leprosum is a type III hypersensitivity reaction presenting as erythematous, tender papulo-nodules, commonly on extremities, with histology showing granulomatous inflammation with neutrophil infiltration, and variable degrees of panniculitis and vasculitis.[1,2] Reported incidence of ENL in multibacillary leprosy (especially LL) is as high as 11.8%.[3] The lesions usually appear after starting MDT, although it may sometimes be the presenting feature.[4] Rarely, ENL may be associated with ulceration, producing necrotic ENL, also called erythema necroticans. Necrotic ENL is a severe form often associated with systemic complications and heals with scarring.[5] The case illustrates that lichenoid skin nodules may be an unusual initial presentation of necrotic ENL.
  5 in total

1.  Epidemiological characteristics of leprosy reactions: 15 years experience from north India.

Authors:  Bhushan Kumar; Sunil Dogra; Inderjeet Kaur
Journal:  Int J Lepr Other Mycobact Dis       Date:  2004-06

2.  Comparing the clinical and histological diagnosis of leprosy and leprosy reactions in the INFIR cohort of Indian patients with multibacillary leprosy.

Authors:  Diana N J Lockwood; Peter Nicholls; W Cairns S Smith; Loretta Das; Pramila Barkataki; Wim van Brakel; Sujai Suneetha
Journal:  PLoS Negl Trop Dis       Date:  2012-06-26

3.  A retrospective analysis of histopathology of 64 cases of lepra reactions.

Authors:  Vijay Adhe; Atul Dongre; Uday Khopkar
Journal:  Indian J Dermatol       Date:  2012-03       Impact factor: 1.494

4.  Necrotic Erythema Nodosum Leprosum Healing with Extensive Scars.

Authors:  Chandra S Sirka; Maitreyee Panda; Swetalina Pradhan; Manas R Baisakh
Journal:  Indian Dermatol Online J       Date:  2017 Nov-Dec

5.  Atypical erythema nodosum leprosum as the presenting feature in multibacillary leprosy: a case report.

Authors:  Sanchaita Bala; Sumit Sen; Gobinda Chatterjee; Anusree Gangopadhyay
Journal:  Indian J Dermatol       Date:  2014-01       Impact factor: 1.494

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.